saplin

Compare funds

UTI - Flexi Cap vs SBI Flexicap

Both are flexi cap funds. Over the last 3 years UTI - Flexi Cap returned 10.2% a year and SBI Flexicap 10.2%, against a category median of 13.5%. UTI - Flexi Cap costs 1.17% a year and SBI Flexicap 1.25%. On the saplin Score UTI - Flexi Cap rates 5.5 (Weak) and SBI Flexicap 4.9 (Weak) within their category. 30.7% of their money is in the same stocks.

Direct plans, growth option. Returns and risk as of 15 Nov 2026; past performance does not tell you future returns. See both side by side with charts.

At a glance

UTI - Flexi CapSBI FlexicapCategory median
saplin Score (0–10)5.5 Weak4.9 Weak—
1-year return2.9%0.3%5.0%
3-year return, a year10.2%10.2%13.5%
5-year return, a year4.8%8.2%11.0%
Volatility (standard deviation)15.4%14.2%16.0%
Sharpe ratio0.300.310.51
Beta0.880.870.95
Upside capture8885102
Downside capture928995
Expense ratio (Direct)1.17%1.25%0.93%
Fund size₹23,664 cr₹22,863 cr₹4,814 cr
Number of holdings526167
Top 10 holdings, share of fund46.0%35.8%35.8%
Portfolio P/E36.727.626.2
Lead managerAjay Tyagi (11 yrs)Anup Upadhyay (2 yrs)—
Launched1 Aug 199229 Sept 2005—

Green marks the higher return, Sharpe ratio, upside capture and Score, and the lower volatility, downside capture and cost. That is the direction of each measure, not a recommendation.

Portfolio overlap

UTI - Flexi Cap and SBI Flexicap have 30.7% of their portfolios in the same stocks (12 holdings in common, portfolios as of 31 Oct 2026). Overlap is the smaller of the two weights in each shared holding, added up: 100% would be identical portfolios.

Biggest shared holdingsUTI - Flexi CapSBI Flexicap
ICICI Bank6.15%7.45%
HDFC Bank4.47%5.60%
Bharti Airtel3.80%3.78%
Coforge4.35%2.97%
Bajaj Finance5.33%2.50%
Titan Company3.84%2.39%
Eicher Motors2.21%2.54%
Eternal6.97%2.17%
Kotak Mahindra Bank3.65%1.87%
Divi's Laboratories1.83%1.22%

The funds

How the Score works: methodology. Check any set of funds with the overlap checker.

More comparisons

saplin is not registered with SEBI. This page compares published data and is not a recommendation to buy, hold or sell either fund.